(Total Views: 310)
Posted On: 07/15/2020 8:59:13 AM
Post# of 36566
From the paper doc submitted below:
Finally, a likely continued major challenge for peptide vaccines will be the weaker overall immune response that subunit vaccines tend to elicit in comparison to vaccines that contain inactivated or attenuated pathogen.
How is GNBT overcoming this seemingly significant limitation?
Finally, a likely continued major challenge for peptide vaccines will be the weaker overall immune response that subunit vaccines tend to elicit in comparison to vaccines that contain inactivated or attenuated pathogen.
How is GNBT overcoming this seemingly significant limitation?
(0)
(0)
